The news is directly about Stoke Therapeutics. The Overweight rating suggests that the analyst expects the stock to outperform the market, which is positive. However, the lowering of the price target from $18 to $14 indicates a reduced future valuation, which could have a negative impact. The net effect is likely to be neutral in the short term.